Characterisation of patients with chronic obstructive pulmonary disease initiating single-device inhaled corticosteroids/long-acting β < sub > 2 < /sub > -agonist dual therapy in a primary care setting in England
CONCLUSION: Patient characteristics, prior treatments, prior COPD-related HCRU and direct healthcare costs were similar across single-device ICS/LABAs in primary care in England. A high proportion of patients were not receiving any respiratory medication pre-index, indicating that prescribing in primary care in England is more closely aligned with national guidelines than global treatment strategies. Comorbid asthma may have influenced prescribing decisions. Less than half of users had preindex exacerbations, suggesting that ICS/LABA is not being prescribed principally based on exacerbation history.PMID:36171051 | DOI:10.1...
Source: Respiratory Care - September 28, 2022 Category: Respiratory Medicine Authors: Alexandrosz Czira Victoria Banks Gema Requena Robert Wood Theo Tritton Rosie Wild Chris Compton Maria Duarte Afisi S Ismaila Source Type: research
Characterisation of patients with chronic obstructive pulmonary disease initiating single-device inhaled corticosteroids/long-acting β < sub > 2 < /sub > -agonist dual therapy in a primary care setting in England
CONCLUSION: Patient characteristics, prior treatments, prior COPD-related HCRU and direct healthcare costs were similar across single-device ICS/LABAs in primary care in England. A high proportion of patients were not receiving any respiratory medication pre-index, indicating that prescribing in primary care in England is more closely aligned with national guidelines than global treatment strategies. Comorbid asthma may have influenced prescribing decisions. Less than half of users had preindex exacerbations, suggesting that ICS/LABA is not being prescribed principally based on exacerbation history.PMID:36171051 | DOI:10.1...
Source: Respiratory Care - September 28, 2022 Category: Respiratory Medicine Authors: Alexandrosz Czira Victoria Banks Gema Requena Robert Wood Theo Tritton Rosie Wild Chris Compton Maria Duarte Afisi S Ismaila Source Type: research
Using SMART Regimens in PHM
PHM Session: Get SMART: Implementation of updated asthma guidelines for pediatric hospitalists
Presenters: Alexander Hogan, MD, MS, Connecticut Children’s Medical Center, Hartford, Conn., Kathryn Kyler, MD, MSc, and Claire Seguin, MD, Children’s Mercy Kansas City, Mo.
This session focused on how pediatric hospitalists can improve the asthma care of patients discharged from hospitalizations by instituting single maintenance and reliever therapy (SMART) regimens. More specifically, this is a single inhaler that includes both an inhaled corticosteroid (ICS) and a long-acting beta-agonist (LABA), which have U.S. Food and D...
Source: The Hospitalist - September 23, 2022 Category: Hospital Management Authors: Lisa Casinger Tags: Adolescent Medicine Asthma Clinical Guidelines Pediatrics Source Type: research
Using SMART Regimens in PM
PHM Session: Get SMART: Implementation of updated asthma guidelines for pediatric hospitalists
Presenters: Alexander Hogan, MD, MS, Connecticut Children’s Medical Center, Hartford, Conn., Kathryn Kyler, MD, MSc, and Claire Seguin, MD, Children’s Mercy Kansas City, Mo.
This session focused on how pediatric hospitalists can improve the asthma care of patients discharged from hospitalizations by instituting single maintenance and reliever therapy (SMART) regimens. More specifically, this is a single inhaler that includes both an inhaled corticosteroid (ICS) and a long-acting beta-agonist (LABA), which have U.S. Food and D...
Source: The Hospitalist - September 23, 2022 Category: Hospital Management Authors: Lisa Casinger Tags: Adolescent Medicine Asthma Clinical Guidelines Pediatrics Source Type: research
Narrative Review of the Role of Patient-Reported Outcomes and Inhaler Handling Errors in the Control of Asthma and COPD
AbstractPurpose of ReviewAsthma and chronic obstructive pulmonary disease (COPD) are chronic respiratory diseases that remain uncontrolled in many patients, despite the wide range of therapeutic options available. This review analyzes the available clinical evidence on 3 budesonide/formoterol DPI devices, Spiromax®, Turbuhaler®, and Easyhaler®, in terms of patient-reported outcomes (PROs), inhaler errors, and asthma and COPD control.Recent FindingsThe effectiveness of dry powder inhalers (DPI) depends largely on the device and the patient ’s inhaler technique. Equally important are the patient’s perception of the in...
Source: Current Allergy and Asthma Reports - September 10, 2022 Category: Allergy & Immunology Source Type: research
Repeated dose budesonide/formoterol compared to salbutamol in adult asthma: a randomised crossover trial
Conclusions
The comparative bronchodilator responses of repeated administration of salbutamol 200 µg and budesonide/formoterol 200/6 µg differed depending on the time of measurement. Salbutamol caused greater systemic β2-agonist and cardiovascular effects and more adverse events. (Source: European Respiratory Journal)
Source: European Respiratory Journal - September 7, 2022 Category: Respiratory Medicine Authors: Kearns, N., Bruce, P., Williams, M., Doppen, M., Black, M., Weatherall, M., Beasley, R. Tags: Asthma and allergy Original Articles: Asthma Source Type: research
Correction to: Adherence and quality of life assessment in patients with asthma treatment with budesonide/formoterol via the Elpenhaler device: the COMPLETE study
(Source: BMC Pulmonary Medicine)
Source: BMC Pulmonary Medicine - August 23, 2022 Category: Respiratory Medicine Authors: Konstantinos P. Exarchos, Nikoletta Rovina, George Krommidas, Dimitrios Latsios, Athena Gogali and Konstantinos Kostikas Tags: Correction Source Type: research
Oral leukoplakia in a smoking patient using inhaled formoterol and budesonide
A 67-year-old non-White female patient was referred to our service for evaluation of a white oral lesion. The patient reported being a heavy smoker for 56 years and a 15-year history of asthma controlled with inhaled formoterol fumarate and budesonide for 15 years. Extraoral examination showed no relevant alterations. Intraoral examination revealed a nondetachable white verrucous plaque on the right side of the soft palate close to the limit with the hard palate. The lesion measured approximately 1.5 × 1.0 cm and had regular borders and well-defined limits. (Source: Oral Surgery, Oral Medicine, Oral Pathology, Oral R...
Source: Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics - August 17, 2022 Category: ENT & OMF Authors: Diovana De Melo Cardoso, J éssica Silva Santana, Maria Clara Bertolini Botelho, Vitor Bonetti Valente, Marcelo Macedo Crivelini, Éder Ricardo Biasoli, Daniel Galera Bernabé Source Type: research
SMART in treatment of asthma exacerbations
CONCLUSION: Although not all studies demonstrated the effectiveness of SMART, the majority revealed a significant reduction in asthma exacerbation frequency and severity.PMID:35914659 | DOI:10.1016/j.anai.2022.07.024 (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - August 1, 2022 Category: Allergy & Immunology Authors: Syed Fahmeed Imam Saira Zafar John Oppenheimer Source Type: research
SMART in treatment of asthma exacerbations
CONCLUSION: Although not all studies demonstrated the effectiveness of SMART, the majority revealed a significant reduction in asthma exacerbation frequency and severity.PMID:35914659 | DOI:10.1016/j.anai.2022.07.024 (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - August 1, 2022 Category: Allergy & Immunology Authors: Syed Fahmeed Imam Saira Zafar John Oppenheimer Source Type: research
Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis
ConclusionThe findings of this NMA suggest favorable efficacy with single-inhaler triple therapy comprising FF/UMEC/VI. Further analysis is required as additional evidence becomes available. (Source: Advances in Therapy)
Source: Advances in Therapy - July 17, 2022 Category: Drugs & Pharmacology Source Type: research
Stepped treatment algorithm using budesonide-formoterol for chronic respiratory diseases: A single arm interventional study
ConclusionThis novel therapeutic algorithm is feasible for patients with chronic respiratory diseases in a rural setting in Vietnam. Further studies are required to establish the effectiveness, safety and cost-effectiveness of similar approaches in different settings. Trial registrationACTRN12619000554167. (Source: PLoS One)
Source: PLoS One - July 11, 2022 Category: Biomedical Science Authors: Wan-Chun Huang Source Type: research
